We’re no longer requiring prior authorization for 29 medical oncology drugs

We’re no longer requiring prior authorization from AIM Specialty Health^® for dates of service on or after Jan. 1, 2023 for 29 medical oncology drugs. These drugs are part of members’ medical benefits.
This change applies to:

• Blue Cross Blue Shield of Michigan commercial groups
• Members with coverage through fully insured groups
• Members with coverage through self-funded groups that have opted into the medical oncology program (Refer to the AIM medical oncology prior authorization program opt-in list for Blue Cross commercial self-funded groups.)
• Members with individual coverage
• Medicare Plus Blue℠ members
• Blue Care Network commercial members
• BCN Advantage℠ members

Drugs affected by this change

The following drugs are affected by this change:

**The manufacturer is withdrawing this drug from the market.
***Requires prior authorization by AIM for Medicare Advantage members only, for dates of service through Dec. 31, 2022.

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

• Blue Cross and BCN commercial members:
• Medical oncology prior authorization list for Blue Cross commercial fully insured and BCN commercial members
• Blue Cross and BCN utilization management medical drug list
• URMBT members with Blue Cross non-Medicare plans:
• Medical oncology prior authorization list for UAW Retiree Medical Benefits Trust PPO non-Medicare members
• Medical Drug Management with Blue Cross for UAW Retiree Medical Benefit Trust PPO non-Medicare Members
• Medicare Plus Blue and BCN Advantage members:
• Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members

We’ve updated the appropriate drug lists to reflect the information in this article.

AIM Specialty Health is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage authorizations for select services.